Wyeth

Other

Kraft Foods Group Brands LLC

Alexander Greenfield

Craig E Caufield

Albert Jean Robichaud

John Anthony Butera

Robert E McDevitt

Lisa Marie Havran

Hassan Mahmoud Elokdah

Scott Christian Mayer

Alan Howard Katz

Joseph R Lennox

Eric Gould Gundersen

Cristina Grosanu

Russell Graceffa

Kevin G Liu

Geraldine Ruth McFarlane

Joseph Peter Sabatucci

Jennifer Rebecca Lo

Eamonn P Morrison

Boyd Lynn Harrison

Gary Paul Stack

Wayne Everett Childers

Ronald Charles Bernotas

Donna Mary Huryn

Paul Jeffrey Dollings

Jonathan Laird Gross

Arlene J Dietrich

Koi Morris

Schuyler Adam Antane

Yanfang Li

Surendra H Agarwal

Russell F Graceffa

Ying (Lora) Liang

James Jacob Bicksler

Chae-Koo Dan Chong

Vasilios Marathias

John Dunlop

An oxygen scavenging polyolefin composition and methods of making thereof are described herein. In one approach, the composition includes a continuous non-polar polyolefin matrix having oxygen scavenging domains dispersed therein. The oxygen scavenging domains include an oxidizable polymer, a transition metal catalyst or salt thereof, and a catalytic promoter effective to bind with oxygen passing through the continuous non-polar polyolefin matrix. The oxygen scavenging domains forming a discrete polar region within the continuous non-polar polyolefin matrix. The composition further includes a polymeric compatibilizer having a polar moiety and a non-polar moiety and in amounts effective to uniformly disperse the polar oxygen scavenging domains in the continuous non-polar polyolefin matrix.

Oxygen scavenger system in a polyolefin matrix

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. 

Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor 

Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders

Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands

Novel pyrimidoindolone compounds are disclosed. Methods of using the pyrimidoindolone compounds and compositions containing the compounds in the treatment and/or prevention of disease and other conditions related to inflammation, neurodegeneration, osteoarthritis and apoptosis are also disclosed.

Pyrimidoindolones and methods for using same

This invention provides compounds of Formula I having the structureor a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia

This invention provides compounds of formula I, having the structurewherein R, R, A, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof, that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia.

Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus

This invention provides compounds of formula I, having the structurewherein R, R, R, R, A, and B are as defined in the specification, or a pharmaceutically acceptable salt thereof, that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia.

Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM)

Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine as inhibitors of glutamate transport

Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine

This invention provides compounds of Formula I having the structure

Growing community of inventors

West Windsor, NJ, United States of America

Alexander Greenfield